CIVO Platform Clinical Validation
Solid Tumors (e.g., Lymphoma, Sarcoma)
Early ClinicalActive
Key Facts
Indication
Solid Tumors (e.g., Lymphoma, Sarcoma)
Phase
Early Clinical
Status
Active
Company
About Presage Biosciences
Presage Biosciences is pioneering a novel approach to cancer drug development with its CIVO platform, a translational tool that allows for the safe, simultaneous testing of multiple microdosed therapies in a single patient's tumor. This technology bridges a critical gap between preclinical models and clinical trials by providing high-resolution, spatial data on molecular and cellular responses in the actual human tumor microenvironment. The company operates both a preclinical services business and has advanced the platform into clinical studies with pharmaceutical partners. Its mission is to de-risk and accelerate oncology drug development by delivering more predictive human data early in the process.
View full company profile